Resorcinol: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
m (Protected "Resorcinol": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(11 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{Chembox new
{{DrugProjectFormSinglePage
|authorTag={{Ammu}}
|OTC=Yes
|genericName=sulfur and resorcinol
|aOrAn=an
|drugClass=anti [[acne]] agent
|indicationType=treatment
|indication=management of [[acne]]
|adverseReactions=[[hypersensitivity]]
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult=* Uses for the management of [[acne]]
* Penetrates pores to control [[acne]] blemishes, [[acne]] pimples, blackheads and whiteheads
* Helps keep skin clear of new [[acne]] blemishes, [[acne]] pimples, blackheads and whiteheads.
=====Directions=====
* Shake well
* Cleanse he skin thoroughly before applying the medication
* Cover the entire affected area with a thin layer one to three times daily
* Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor
* If bothersome dryness or peeling occurs, reduce application to once a day or every other day.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=<!--Warnings-->
|warnings=* For external use only
* Flammable, Keep away from fire or flame
* Do not use on broken skin, on large areas of the body
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|drugInteractions=<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* [[Topical]]
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox={{chembox2
| Verifiedfields = changed
| verifiedrevid = 415763656
|  Name = Resorcinol
|  Name = Resorcinol
|  ImageFile = Resorcine.svg
|  ImageFileL1 = Resorcinol.png
<!-- | ImageSize = 150px -->
|  ImageNameL1 = Skeletal formula
|  ImageName = Resorcinol
|  ImageFileR1 = Resorcinol-3D-balls.png
|  ImageFile1 = Resorcinol-3d.png
|   ImageNameR1 = Ball-and-stick model
<!-- | ImageSize1 = 150px  -->
|  IUPACName = Benzene-1,3-diol
|  IUPACName = Resorcinol
|  OtherNames = Resorcin<br />m-dihydroxybenzene; 1,3-benzenediol; 1,3-Dihydroxybenzene; 3-Hydroxyphenol; m-hydroquinone; m-benzenediol; 3-hydroxycyclohexadien-1-one
|  OtherNames = Resorcin<br />Benzene-1,3-diol
| Section1 = {{Chembox Identifiers
| Section1 = {{Chembox Identifiers
|  SMILES = Oc1cc(O)ccc1
|  ChEBI_Ref = {{ebicite|changed|EBI}}
|   CASNo = 108-46-3
| ChEBI = 27810
| SMILES = c1cc(cc(c1)O)O
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4878
| PubChem = 5054
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 24147
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YUL4LO94HK
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00133
| InChI = 1/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H
| InChIKey = GHMLBKRAJCXXBS-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GHMLBKRAJCXXBS-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 108-46-3
| UNNumber = 2876
| ATCCode_prefix = D10
| ATCCode_suffix = AX02
| ATC_Supplemental = {{ATC|S01|AX06}}
   }}
   }}
| Section2 = {{Chembox Properties
| Section2 = {{Chembox Properties
|  Formula = C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub>
|  Formula = C<sub>6</sub>H<sub>6</sub>O<sub>2</sub>
|  MolarMass = 110.1 g/mol
|  MolarMass = 110.1 g/mol
|  Appearance = white solid
|  Appearance = White solid
|  Density = 1.28 g/cm<sup>3</sup>, solid
|  Density = 1.28 g/cm<sup>3</sup>, solid
|  Solubility = 140 g/100 ml (? °C)
|  Solubility = 110 g/100 mL at 20 °C
|  MeltingPt = 110 °C
|  MeltingPtC = 110
|  BoilingPt = 280 °C
|  BoilingPtC = 277
|  pKa =  
|  pKa = 9.15<ref>Gawron, O., Duggan, M., Grelechi, C., ''J. Anal. Chem.'', '''1952''', ''24'', 969.</ref>
   }}
   }}
| Section3 = {{Chembox Structure
| Section3 = {{Chembox Structure
Line 27: Line 132:
| Section7 = {{Chembox Hazards
| Section7 = {{Chembox Hazards
|  ExternalMSDS =
|  ExternalMSDS =
|  FlashPtF = 261
|  EUClass = Harmful ('''Xn''')<br />Dangerous for<br />the environment ('''N''')
|  EUClass = Harmful ('''Xn''')<br />Dangerous for<br />the environment ('''N''')
   }}
   }}
}}
}}
{{SI}}
|mechAction=<!--Structure-->
|structure=<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.


==Overview==
<!--Nonclinical Toxicology-->
'''Resorcinol''' (or '''resorcin''') is a [[chemical compound]] from the dihydroxy [[phenol]]s. it is the 1,3-[[isomer]] of [[benzenediol]]. It is also known with a variety of other names, including: m-dihydroxybenzene, 1,3-benzenediol, 1,3-dihydroxybenzene, 3-hydroxyphenol, m-hydroquinone, m-benzenediol, and 3-hydroxycyclohexadien-1-one.
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


==Nomenclature==
<!--Clinical Studies-->
Resorcinol is the name recommended by the [[International Union of Pure and Applied Chemistry]] (IUPAC) in its ''1993 Recommendations for the Nomenclature of Organic Chemistry''.{{ref|BlueBook}}
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


==Production==
<!--How Supplied-->
It is obtained on fusing many [[resin]]s ([[galbanum]], [[asafoetida]], etc.) with [[potassium hydroxide]], or by the [[distillation]] of [[Brazilwood]] extract. It may be prepared [[organic synthesis|synthetically]] by fusing [[3-Iodophenol|3-iodophenol]], [[phenol-3-sulfonic acid]] or [[benzene-1,3-disulfonic acid]] with [[potassium carbonate]]; by the action of [[nitrous acid]] on [[3-Aminophenol|3-aminophenol]]; or by the action of 10% [[hydrochloric acid]] on [[1,3-diaminobenzene]] (J. Meyer, Ber., 1897, 30, p. 2569). Many ''ortho''- and ''para''-compounds of the [[aromatic]] series (for example, the bromophenols, benzene-''para''-disulfonic acid) also yield resorcinol on fusion with potassium hydroxide. also is a two ball screw ball.
|packLabel=[[File:Resorcinol 01.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]]
[[File:Resorcinol 02.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


==Properties==
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


Resorcinol crystallizes from [[benzene]] as colorless needles which are readily soluble in water, alcohol and ether, but insoluble in [[chloroform]] and [[carbon disulfide]]. It reduces [[Fehling's solution]], and [[Tollens' reagent|ammoniacal silver solutions]]. It does not form a precipitate with [[lead acetate]] solution, as the isomeric [[pyrocatechol]] does. [[Iron(III) chloride]] colors its aqueous solution a dark violet, and [[bromine]] water precipitates tribromoresorcin. [[Sodium amalgam]] reduces it to dihydroresorcin, which when heated to 150 to 160 °C with concentrated [[barium hydroxide]] solution gives γ-acetylbutyric acid (D. Vorlgnder); when fused with potassium hydroxide, resorcinol yields [[phloroglucin]], pyrocatechol and [[diresorcin]]. It [[condensation reaction|condenses]] with [[acid]]s or [[acid chloride]]s, in the presence of dehydrating agents, to oxyketones, e.g. with [[zinc chloride]] and glacial [[acetic acid]] at 145 °C it yields resacetophenone (HO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>~CO.CH<sub>3</sub>(M. Nencki and N. Sieber, Jour. prak. Chem., 1881, 23, p. 147). With the [[anhydride]]s of dibasic acids it yields [[fluorescein]]s. When heated with [[calcium chloride]]&mdash;[[ammonia]] to 200 °C it yields meta-dioxydiphenylamine (A. Seyewitz, Bull. Soc. Chins., 1890, 3, p. 811). With [[sodium nitrite]] it forms a water-soluble blue dye, which is turned red by acids, and is used as an [[indicator]], under the name of lacmoid (M. C. Traub and C. Hock, Ber., 1884, 17, p. 2615). It condenses readily with [[aldehyde]]s, yielding with [[formaldehyde]], on the addition of catalytic [[hydrochloric acid]], methylene diresorcin [(HO)C<sub>6</sub>H<sub>3</sub>(O)]<sub>2</sub>•CH<sub>2</sub>, whilst with [[chloral hydrate]], in the presence of [[Potassium hydrogensulfate|potassium bisulfate]], it yields the [[lactone]] of tetra-oxydiphenyl methane carboxylic acid (J. T. Hewitt and F. G. Pope, Jour. C/tern. Soc., 1897, 75, p. 1084). In alcoholic solution it condenses with [[sodium acetoacetate]] to form 13-methylumbelliferone, C~OH<sub>8</sub>O<sub>3</sub> (A. Michael, Jour. prak. Chem., 1888, 37, 470).
<!--Brand Names-->
|brandNames=* ACNOTEX ACNE TREATMENT®<ref>{{Cite web | title = ACNOTEX ACNE TREATMENT - sulfur and resorcinol lotion  | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89bc8aff-8cd7-41ed-8619-11cd2dd5ffde  }}</ref>


With concentrated [[nitric acid]], in the presence of cold concentrated [[sulfuric acid]], it yields trinitro-resorcin ([[styphnic acid]]), which forms yellow crystals, exploding violently on rapid heating.
<!--Look-Alike Drug Names-->
|drugShortage=
}}


==Applications==
<!--Pill Image-->
===Medical===
Used externally it is an [[antiseptic]] and [[disinfectant]], and is used 5 to 10% in ointments in the treatment of chronic skin diseases such as [[psoriasis]] and [[eczema]] of a sub-acute character. It is present in over-the-counter topical acne treatments at 2% concentration, and in prescription treatments at higher concentrations. Weak, watery solutions of resorcinol (10 or 15 [[grain (unit)|grains]] to the ounce, or 25 to 35 g/kg) are useful in allaying the itching in erythematous eczema. A 2% solution used as a spray has been used with marked effect in [[hay fever]] and in [[whooping cough]]. In the latter disease 0.6 mL of the 2% solution has been given internally. It can be included as an anti-dandruff agent in shampoo or in sunscreen cosmetics. It has also been employed in the treatment of gastric ulcer in doses of 125 to 250 mg in pills, and is said to be analgesic and haemostatic in its action. In large doses it is a poison causing giddiness, deafness, salivation, sweating and convulsions. It is also worked up in certain medicated soaps. Monoacetylresorcinol, C<sub>6</sub>H<sub>4</sub>(OH)(O-COCH<sub>3</sub>), is used under the name of '''euresol'''.


===Chemical===
Resorcinol is also used as a chemical intermediate for the synthesis of pharmaceuticals and other organic compounds. It is used in the production of diazo dyes and plasticizers and as a [[UV]] absorber in resins.


An emerging use of resorcinol is as a template molecule in [[supramolecular chemistry]].  The -OH groups on resorcinol form [[hydrogen bond]]s to target molecules holding them in the proper orientation for a reaction.  Many such reactions are able to be carried out in the [[Phase (matter)|solid state]] thereby reducing or eliminating the use of solvents that may be harmful to the environment. (see [[Green chemistry]])


Resorcinol is an analytical reagent for the qualitative determinaion of ketoses ([[Seliwanoff's test]]).
<!--Label Display Image-->


Resorcinol is the starting material for [[resorcinarene]] molecules.


==Related compounds==
Resazurin, C<sub>12</sub>H<sub>7</sub>NO<sub>4</sub>, obtained by the action of nitrous acid on resorcinol (P. Weselsky and R. Benedikt, Monats., 1880, f, p. 889), forms small dark red crystals possessing a greenish metallic glance. When dissolved in concentrated sulphuric acid and warmed to 210 °C, the solution on pouring into water yields a precipitate of resorufin, C<sub>12</sub>H<sub>7</sub>NO<sub>3</sub>, an oxyphenoxazone, which is insoluble in water, but is readily soluble in hot concentrated hydrochloric acid, and in solutions of caustic alkalis. The alkaline solutions are of a rose-red color and show a cinnabar-red fluorescence. A tetrabromresorufin is used as a dye-stuff under the name of Fluorescent Resorcin Blue.


Thioresorcinol is obtained by the action of zinc and hydrochloric acid on the chloride of benzene meta-disulphonic acid. It melts at 27 °C and boils at 243 °C. Resorcinol disulfonic acid (HO)<sub>2</sub>C<sub>6</sub>H<sub>2</sub>(HSO3)<sub>2</sub>, is a deliquescent mass obtained by the action of sulphuric acid on resorcin (H. Fischer, Monats., 1881, 2, p. 321). It is easily soluble in water and decomposes when heated to 100 °C.


==Reference==
#{{note|BlueBook}} {{cite book | author=Panico, R.; & Powell, W. H. (Eds.) | title=A Guide to IUPAC Nomenclature of Organic Compounds 1993 | location=Oxford | publisher=Blackwell Science | year=1994 | id=ISBN 0-632-03488-2}}


==References==
<!--Category-->


<references/>
[[Category:Drug]]
 
==External links==
*[http://www.ilo.org/public/english/protection/safework/cis/products/icsc/dtasht/_icsc10/icsc1033.htm International Chemical Safety Card 1033]
*[http://www.cdc.gov/niosh/npg/npgd0543.html NIOSH Pocket Guide to Chemical Hazards]
*[http://www-cie.iarc.fr/htdocs/monographs/vol71/046-resorcinol.html IARC Monograph: "Resorcinol"]
*{{ecb}}
*[http://www.acdlabs.com/iupac/nomenclature/ IUPAC Nomenclature of Organic Chemistry] (online version of the "''Blue Book''")
 
{{1911}}
 
[[Category:Benzenediols]]
[[Category:Phenols]]
[[Category:IARC Group 3 carcinogens]]
[[Category:IARC Group 3 carcinogens]]
[[Category:Photographic chemicals]]
[[ar:ريزورسينول]]
[[de:Resorcin]]
[[es:Resorcinol]]
[[fr:Résorcine]]
[[it:Resorcinolo]]
[[lv:Rezorcīns]]
[[nl:Resorcinol]]
[[ja:レゾルシノール]]
[[pl:Rezorcyna]]
[[pt:Resorcina]]
[[ru:Резорцин]]
[[fi:Resorsinoli]]
{{WH}}
{{WS}}

Latest revision as of 17:04, 20 August 2015

Resorcinol
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Resorcinol is an anti acne agent that is FDA approved for the treatment of management of acne. Common adverse reactions include hypersensitivity.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Uses for the management of acne
  • Penetrates pores to control acne blemishes, acne pimples, blackheads and whiteheads
  • Helps keep skin clear of new acne blemishes, acne pimples, blackheads and whiteheads.
Directions
  • Shake well
  • Cleanse he skin thoroughly before applying the medication
  • Cover the entire affected area with a thin layer one to three times daily
  • Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor
  • If bothersome dryness or peeling occurs, reduce application to once a day or every other day.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Resorcinol in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Resorcinol in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Resorcinol in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Resorcinol in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Resorcinol in pediatric patients.

Contraindications

There is limited information regarding Resorcinol Contraindications in the drug label.

Warnings

  • For external use only
  • Flammable, Keep away from fire or flame
  • Do not use on broken skin, on large areas of the body

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Resorcinol in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Resorcinol in the drug label.

Drug Interactions

There is limited information regarding Resorcinol Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Resorcinol in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Resorcinol during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Resorcinol with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Resorcinol with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Resorcinol with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Resorcinol with respect to specific gender populations.

Race

There is no FDA guidance on the use of Resorcinol with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Resorcinol in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Resorcinol in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Resorcinol in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Resorcinol in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Resorcinol in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Resorcinol in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Resorcinol in the drug label.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox UNNumberTemplate:Chembox AppearanceTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SolubilityInWaterTemplate:Chembox pKaTemplate:Chembox StructureTemplate:Chembox EUClassTemplate:Chembox FlashPtTemplate:Chembox Supplement
Template:Chembox header2 | Resorcinol
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
KEGG
UNII
Properties
C6H6O2
Molar mass 110.1 g/mol
Hazards
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

There is limited information regarding Resorcinol Mechanism of Action in the drug label.

Structure

There is limited information regarding Resorcinol Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Resorcinol in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Resorcinol in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Resorcinol in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Resorcinol in the drug label.

How Supplied

There is limited information regarding Resorcinol How Supplied in the drug label.

Storage

There is limited information regarding Resorcinol Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Resorcinol |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.

{{#ask: Label Page::Resorcinol |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Resorcinol in the drug label.

Precautions with Alcohol

  • Alcohol-Resorcinol interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • ACNOTEX ACNE TREATMENT®[2]

Look-Alike Drug Names

There is limited information regarding Resorcinol Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Gawron, O., Duggan, M., Grelechi, C., J. Anal. Chem., 1952, 24, 969.
  2. ↑ "ACNOTEX ACNE TREATMENT - sulfur and resorcinol lotion".
Retrieved from "https://www.wikidoc.org/index.php?title=Resorcinol&oldid=1137398"